By: Tomas Ronolski - AllPennyStocks.com News

Monday, May 4, 2015

The growing risk of global terrorism has made the U.S. vulnerable to chemical and radiological weapon attacks. Not surprisingly, the U.S. government agencies have been spending heavily on countermeasures against chemical and radiological weapons. In 2009, President Obama said, “Although it is entirely feasible to mitigate the impact of even a large-scale biological attack upon a city’s population, doing so incurs a significant cost and effort. We therefore need to place increased priority on actions to further reduce the likelihood that such an attack might occur.” The priority is on making sure attacks of such nature (biological, chemical and radiological) are prevented. However, still government agencies need to develop countermeasures in case such attacks do occur.

Several private players have been developing such countermeasures, with funding from the U.S. government. One such company is Mission Viejo, California-based Aeolus Pharmaceuticals Inc. (OTCQB:AOLS). The company is engaged in the development of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation.

AEOL 10150 is a compound being developed by AOLS. The development program is receiving funding from the U.S. Department of Health and Human Services. AEOL 10150 is being developed as a medical countermeasure against chemical and radiological weapons. AOLS is initially focusing on developing AEOL 10150 as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation syndrome and delayed effects of acute radiation exposure.

On Monday, the company reported complete results from a study showing AEOL 10150 doubles survival rate following lung damage caused by acute radiation exposure. News of the successful study is expected to boost AOLS shares in trading on Monday. In fact, the stock had rallied in Friday’s trading session as well.

The study showed that 60 days of treatment with AEOL 10150 improved survival from 25% to 50%. The study was conducted by researchers at the University of Maryland School of Medicine (UM SOM) led by Thomas MacVittie, PhD, Professor at the Division of Translational Radiation Sciences.

Commenting on the successful study, MacVittie said that the study conducted in a very severe model of lung injury provided critical evidence for a significant survival-effect as well as helping to define the best treatment protocol for administration of AEOL 10150. MacVittie further said that the final assessment of key secondary parameters indicative of both clinical and radiographic evidence of lung injury showed an overwhelming positive effect of treatment with AEOL 10150.

Copyright © 2015 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.